Generic therapy is available for managing OA pain in horses

A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses. Aurora Pharmaceutical’s EquiCoxib is bioequivalent to the Equioxx brand oral paste (Boehringer Ingelheim) using firocoxib as the active ingredient.^1,2

Approved by the FDA in January 2024, EquiCoxib is a noninvasive, liquid formulation. The FDA permitted the application for EquiCoxib approval to differ in dosage form and strength from the brand product. An in vivo blood-level study in horses was conducted to demonstrate that the 9.0 mg/mL EquiCoxib oral solution is bioequivalent to the 8.2 mg/g Equioxx oral paste. Based on study data submitted to the FDA by Aurora Pharmaceutical, the agency determined that EquiCoxib is safe and effective when used according to its’ label.^1,2

EquiCoxib is indicated for oral administration once a day for up to 14 days in equine patients, and should not be injected. This therapy is available by prescription from a licensed veterinarian, and should not be used with other NSAIDs, corticosteroids or nephrotoxic medication.^1,3

"EquiCoxib is [a]… cost-effective option that doesn't compromise quality," Mike Strobel, DVM, MS, founder and CEO of Aurora Pharmaceutical, said in a news release.¹ "We're excited to share our latest offering to horse owners and their veterinarians."

Aurora Pharmaceutical specializes in developing, manufacturing, and distributing animal health products. Based in Northfield, Minnesota, the company aims to serve veterinarians, livestock producers, and pet owners.¹

With EquiCoxib, Aurora Pharmaceutical is advising veterinarians to provide a client information sheet to the patient’s owner with every prescription and refill. Veterinary professionals and client should be aware of potential risks associated with firocoxib, and clients should also be advised to observed for signs of potential drug toxicity, according to the company.¹

The most common adverse effects associated with EquiCoxib include erosions and ulcers of the gums, tongue, lips and face, and kidney problems. As a NSAID, EquiCoxib may be associated with gastrointestinal, hepatic and renal toxicity. Additional adverse reactions of firocoxib use in horses may also include weight loss, colic, diarrhea, or icterus. Aurora Pharmaceutics recommends that veterinary teams advise clients to discontinue NSAID therapy and contact their veterinarian immediately if any adverse signs of intolerance are observed.^1,3

References

1. Aurora Pharmaceuticals delivers on FDA-approved generic for equine pain relief. Aurora Pharmaceuticals. February 13, 2025. Accessed February 14, 2025. https://prnmedia.prnewswire.com/news-releases/aurora-pharmaceutical-delivers-on-fda-approved-generic-for-equine-pain-relief-302376438.html
2. Freedom of information summary: ANADA 200-766. FDA. January 11, 2024. Accessed February 14, 2025. https://aurorapharmaceutical.com/wp-content/uploads/2024/03/FOI-Summary-oA-200-766-Approved-January-11-2024.pdf
3. EquiCoxib (firocoxib) oral solution for horses. Aurora Pharmaceuticals. Accessed February 14, 2025. https://aurorapharmaceutical.com/wp-content/uploads/2024/07/EquiCoxib-Product-Insert.pdf